Abstract
Background The early termination of long-acting reversible contraceptives raises issues for the healthcare system and has the potential to affect public health. Long-acting reversible contraception is now more widely available and used, although a sizable percentage of women still stop using it. Therefore, this study aims to assess factors associated with the discontinuation of the long-acting reversible contraceptive method among female users of health facilities in Shashemane Town.
Methods A facility-based cross-sectional study was done in Shashemane town among 410 study participants. The study participants were selected by using a systematic random sampling method. Data were collected by using structured interviewer-administered questionnaires and entered into epi-data version 4.6.0.2 and exported to SPSS version 25 for analysis. Bivariate and multivariable logistic regressions were used to examine the association between independent variables and discontinuation of the long-acting reversible contraceptives. The results were presented using the Odds Ratio at 95% CI. P < 0.05 ware used to dictate statistical significance.
Result The overall prevalence of women who removed the long-acting reversible contraceptive method before the due date was 57.2%. Factors such as having an occupation as a housewife, desire to become pregnant, unwarned side effects, effectiveness, and dissatisfaction with the service provided were positively associated with discontinuation of the contraception.
Conclusion and Recommendation The prevalence of the discontinuation of reversible long-acting contraceptives was high. Pre-insertion effective counseling about the benefits, follow-up care and management for side effects, and client reassurance are recommended.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of he manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional ethical review committee of Salale University with the Ethical Approval number of SIU 321/2022
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses: FL: fikruletose6{at}gmail.com, AT: alemtsahytusa{at}gmail.com, DS: kergadegemu{at}gmail.com, YM: yohannes1979{at}gmail.com
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
